Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy

202252 citationsJournal Articlebronze Open Access

Authors

Henry N. Ginsberg · Columbia University

Neil Hounslow · Berkshire Hathaway (United States)

Yusuke Senko · Kowa (Japan)

Hideki Suganami · Kowa (Japan)

Paweł Bogdański · Poznan University of Medical Sciences

R Češka · Charles University

Ákos Kalina ·

Abstract

Pemafibrate is effective, safe, and well-tolerated for the reduction of TG in European populations with hypertriglyceridemia despite statin treatment.

Topics & Keywords

Peroxisome Proliferator-Activated Receptors Lipoproteins and Cardiovascular Health Diabetes, Cardiovascular Risks, and Lipoproteins

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Care

Volume 45, Issue 4, pp. 898-908

DOI: 10.2337/dc21-1288

Field-Weighted Citation Impact: 4.43